Is MDCO a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

502 people get MDCO articles and Market Currents by email alert.

Get email alerts on MDCO »

HEADLINES:

The Medicines Company CEO Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)
Wed, May 15
RECOTHROM Becomes the First and Only Topical Thrombin Indicated for Use in Children Greater Than or Equal to One Month of Age

Marketwire (May 9, 2013)
The Medicines Company to Participate in Bank of America Merrill Lynch 2013 Health Care Conference

Marketwire (May 8, 2013)
Predicting Biotech Stock Moves Using Top Consensus Picks By Legendary Fund Managers
GuruFundPicks • Sun, May 5 • 3 Comments
The Medicines Company's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, Apr 24
The Medicines Company Reports First Quarter 2013 Financial Results

Marketwire (Apr 24, 2013)
The Medicines Company to Announce First Quarter 2013 Financial Results on Wednesday, April 24, 2013

Marketwire (Apr 11, 2013)
Trius: Topline Data From Second Phase III Trial Of Tedizolid Is Imminent
Smith On Stocks • Mon, Mar 18 • 8 Comments
The Medicines Company's CEO Discusses Phase 3 Cangrelor CHAMPION PHOENIX Trial Results and Outlook (Transcript)
Mon, Mar 11 • 1 Comment
The Medicines Company's Intravenous Cangrelor Demonstrates 22% Reduction in Ischemic Events Compared to Oral Clopidogrel

Marketwire (Mar 10, 2013)
The Medicines Company to Host Cangrelor Webcast on Sunday, March 10, 2013

Marketwire (Mar 8, 2013)
The Medicines Company to Participate in RBC Capital Markets' Healthcare Conference

Marketwire (Feb 22, 2013)
The Medicines Company CEO discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 20
The Medicines Company Reports Fourth Quarter and Full Year 2012 Financial Results

Marketwire (Feb 20, 2013)
The Medicines Company to Announce Fourth Quarter and Full Year 2012 Financial Results on Wednesday, February 20, 2013

Marketwire (Feb 12, 2013)
The Medicines Company and Bristol-Myers Squibb Begin Global Alliance for Recothrom(R)

Marketwire (Feb 8, 2013)
Predicting Biotech Stock Moves Based On Consensus Picks By Legendary Fund Managers
GuruFundPicks • Tue, Feb 5 • 3 Comments
Medicines Company Braces For 2015 With Alnylam PCSK9 Deal
EP Vantage • Mon, Feb 4
Fundamentally Sound With An Added Perk: MDCO
Alan Ellman • Fri, Jan 25
The Medicines Company Announces Positive Results in a Phase 3 Trial of Cangrelor in the Treatment of Patients Undergoing PCI

Marketwire (Jan 8, 2013)

To learn more about Seeking Alpha Pro, click here.

Medicines Company Braces For 2015 With Alnylam PCSK9 Deal
EP Vantage • Mon, Feb 4
Fundamentally Sound With An Added Perk: MDCO
Alan Ellman • Fri, Jan 25
The Medicines Company Needs More Options Beyond Angiomax
EP Vantage • Wed, Oct 12, 2011
Why We're Positive on The Medicines Co.
Zacks Investment Research • Thu, Dec 9, 2010
The Medicines Co.: 'Under the Radar' Catalyst Ahead
Tony Pelz • Sun, Jun 13, 2010 • 4 Comments
The Medicines Company: Patent Extension Denied
Zacks Investment Research • Tue, Mar 23, 2010
What Cangrelor Failure Means to Medicines
Zacks Investment Research • Wed, May 13, 2009

Predicting Biotech Stock Moves Using Top Consensus Picks By Legendary Fund Managers
GuruFundPicks • Sun, May 5 • 3 Comments
Trius: Topline Data From Second Phase III Trial Of Tedizolid Is Imminent
Smith On Stocks • Mon, Mar 18 • 8 Comments
Predicting Biotech Stock Moves Based On Consensus Picks By Legendary Fund Managers
GuruFundPicks • Tue, Feb 5 • 3 Comments
Bear Thesis On Trius Therapeutics Seems Flawed
PropThink • Tue, Dec 18, 2012 • 7 Comments
CADX To Receive $14.5M Or $0.15/Share In Non-Dilutive Funds
PropThink • Wed, Dec 12, 2012
Hedge Funds Recognize These Stocks Are Trading At Steep Discounts To Target Price
Kapitall • Tue, Nov 13, 2012 • 7 Comments
4 Small Cap Stocks Looking Strong In Earnings And Liquidity
ZetaKap • Fri, Oct 12, 2012
6 Liquid Small-Cap Healthcare Stocks Projected For Strong Growth
ZetaKap • Thu, Aug 30, 2012
AstraZeneca In Strong Position With Brilinta
Cris Frangold • Mon, Aug 27, 2012 • 1 Comment
An Investment Update On Trius Therapeutics' Tedizolid
Smith On Stocks • Wed, Aug 22, 2012 • 9 Comments
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts During The Next 3 - 9 Months (Part II)
Markus Aarnio • Tue, Aug 21, 2012 • 4 Comments
Tracking George Soros' Portfolio: Q2 2012 Update
John Vincent • Sat, Aug 18, 2012 • 8 Comments
3 Drugmakers Trading Near Highs With Strong Receivable Trends
Kapitall • Thu, Aug 16, 2012
9 Rallying Healthcare Stocks Seeing Strong Sales Trends
Kapitall • Sat, Aug 4, 2012 • 2 Comments
AstraZeneca Offsets Generic Risk With New Drugs
Todd Campbell • Thu, Aug 2, 2012 • 5 Comments
15 Companies Dumped By Insiders
Gutone • Sun, Jul 8, 2012 • 4 Comments
Soros Fund Management's 2012 Equity Liquidations And Reductions (Part 2)
Zvi Bar • Fri, Jun 1, 2012 • 1 Comment
Trius: Tedizolid Prospects In MRSA Lead To Initiation With A Buy
Smith On Stocks • Fri, Jun 1, 2012 • 1 Comment
Tracking George Soros's Portfolio - Q1 2012 Update
John Vincent • Mon, May 21, 2012
Top March 2012 Quarter Picks From $1 Billion Pure-Play Biotech Swiss Hedge Fund BB Biotech
GuruFundPicks • Mon, May 7, 2012 • 1 Comment

The Medicines Company CEO Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)
Wed, May 15
The Medicines Company's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, Apr 24
The Medicines Company's CEO Discusses Phase 3 Cangrelor CHAMPION PHOENIX Trial Results and Outlook (Transcript)
Mon, Mar 11 • 1 Comment
The Medicines Company CEO discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 20
The Medicines' CEO Presents at Deutsche Bank Annual Healthcare Conference (Transcript)
Mon, May 7, 2012
Medicines CEO Discusses Q3 2010 Results - Earnings Call Transcript
Wed, Oct 27, 2010
The Medicines Company, Inc Q2 2010 Earnings Call Transcript
Wed, Jul 28, 2010
The Medicines Company Q1 2010 Earnings Call Transcript
Sat, May 1, 2010
The Medicines Company Q4 2008 Earnings Call Transcript
Wed, Feb 18, 2009
The Medicines Company Q3 2008 Earnings Call Transcript
Wed, Oct 22, 2008
The Medicines Company Q2 2008 Earnings Conference Call Transcript
Wed, Jul 23, 2008
The Medicines Company Q1 2008 Earnings Conference Call Transcript
Wed, Apr 23, 2008
The Medicines Company Q4 2007 Earnings Call Transcript
Wed, Feb 13, 2008

RECOTHROM Becomes the First and Only Topical Thrombin Indicated for Use in Children Greater Than or Equal to One Month of Age

Marketwire (May 9, 2013)
Michael Sincere's Long-Term Trader: Why I stopped using stop loss orders

at MarketWatch.com (May 9, 2013)
The Medicines Company to Participate in Bank of America Merrill Lynch 2013 Health Care Conference

Marketwire (May 8, 2013)
The Medicines Company Reports First Quarter 2013 Financial Results

Marketwire (Apr 24, 2013)
The Medicines Company to Announce First Quarter 2013 Financial Results on Wednesday, April 24, 2013

Marketwire (Apr 11, 2013)
The Medicines Company's Intravenous Cangrelor Demonstrates 22% Reduction in Ischemic Events Compared to Oral Clopidogrel

Marketwire (Mar 10, 2013)
The Medicines Company to Host Cangrelor Webcast on Sunday, March 10, 2013

Marketwire (Mar 8, 2013)
The Medicines Company to Participate in RBC Capital Markets' Healthcare Conference

Marketwire (Feb 22, 2013)
The Medicines Company Reports Fourth Quarter and Full Year 2012 Financial Results

Marketwire (Feb 20, 2013)
The Technical Indicator: Dow, Nasdaq challenge multiyear highs

at MarketWatch.com (Feb 19, 2013)
The Medicines Company to Announce Fourth Quarter and Full Year 2012 Financial Results on Wednesday, February 20, 2013

Marketwire (Feb 12, 2013)
The Medicines Company and Bristol-Myers Squibb Begin Global Alliance for Recothrom(R)

Marketwire (Feb 8, 2013)
The Medicines Company Announces Positive Results in a Phase 3 Trial of Cangrelor in the Treatment of Patients Undergoing PCI

Marketwire (Jan 8, 2013)
The Medicines Company Completes Acquisition of Incline Therapeutics, Inc.

Marketwire (Jan 7, 2013)
The Medicines Company to Participate in JP Morgan Healthcare Conference

Marketwire (Jan 2, 2013)
The Medicines Company Announces Positive Trial Results for Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Marketwire (Dec 20, 2012)
The Medicines Company Agrees to Acquire Incline Therapeutics, Inc.

Marketwire (Dec 12, 2012)
The Medicines Company and Bristol-Myers Squibb Agree to Global Alliance for Recothrom(R)

Marketwire (Dec 12, 2012)
The Medicines Company to Participate in Two Investor Conferences

Marketwire (Nov 21, 2012)
The Medicines Company to Participate in Jefferies Global Healthcare Conference

Marketwire (Nov 8, 2012)

MDCO vs. ETF Alternatives

Company Description

Currently, there's no company description for MDCO.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, April 24, 8:07 AM The Medicines Co (MDCO): Q1 EPS of -$0.21 in-line. Revenue of $155.8M (+23% Y/Y) beats by $3.17M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 24, 12:05 AM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Tuesday, April 23, 5:30 PM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Monday, March 11, 4:18 AM Medicines Co.'s (MDCO) blood thinner Cangrelor was 22% better at cutting heart risks following a stent procedure than the now generic clopidogrel (Plavix) in a wide-ranging trial. It's a bit of comeback for Cangrelor, which Medicines thought it would shelve in 2009 after disappointing earlier trials. However, follow-up studies showed it was better than Plavix. Medicines now plans to file for FDA approval for Cangrelor, which could generate estimated sales of $400M by 2019. (PR) Comment! [Healthcare]
Wednesday, February 20, 3:16 PM The Medicines Company (MDCO +6%) posts a big gain today after its Q4 easily topped estimates this morning. Revenue jumped by 20% Y/Y, boosted by a 77.2% jump in international sales of Angiomax/Angiox. Comment! [Healthcare, Earnings, On the Move]
Wednesday, February 20, 8:08 AM The Medicines Co (MDCO): Q4 EPS of $0.78 beats by $0.27. Revenue of $159.5M (+20.6% Y/Y) beats by $13.41M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 11, 11:00 AM Alnylam Pharmaceuticals (ALNY -3.4%) dips after MLV cut the shares to Hold from Buy. The firm says it prefers to take a cautious stance ahead of pending details of disease-modifying data from its lead partnered programs. One such program is its strategic alliance with The Medicines Co. (MDCO -3%) to develop ALN-PCS, an RNAi therapeutic program for the treatment of hypercholesterolemia. Comment! [Healthcare, On the Move]
Friday, February 8, 3:14 PM The Medicines Company (MDCO +0.6%) says its global license and two-year collaboration with Bristol-Myers (BMY +1.2%) for Recothrom, a recombinant thrombin approved by the FDA as a topical hemostat to control non-arterial bleeding during surgical procedures, has become effective. Comment! [Healthcare, On the Move]
Monday, February 4, 12:49 PM The Medicines Company (MDCO -1.5%) says it's formed an exclusive global alliance with Alnylam Pharmaceuticals (ALNY -2.6%) for the development and commercialization of ALNY's ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia. The deal could net ALNY $205M plus double-digit royalties if the collaboration is successful, and an early-stage trial has already showed success. Comment! [Healthcare]
Monday, February 4, 8:22 AM The Medicines Company (MDCO) is licensing the rights to cholesterol-lowering drug ALN-PCS from Alnylam Pharmaceuticals (ALNY), with Medicines paying $25M up front, as much as $180M in milestones, and then royalties. The treatment inhibits a protein called PCSK9 and is seen as an alternative to statins such as Lipitor. However, ALN-PCS is only in Phase I trials. Comment! [Healthcare]
Tuesday, January 8, 11:48 AM Medicines Co. (MDCO +10%) pushes through a 6-year high today as the stock surges after the drug maker announces positive Phase 3 trial results of its antiplatelet drug Cangrelor. Cangrelor demonstrated statistically significant improvement compared to clopidogrel, and MDCO intends to submit the results in the U.S. and E.U. for regulatory review in 2013. Comment! [Healthcare, On the Move]
Thursday, December 20, 2012, 3:31 PM Leerink ups its price target for The Medicines Co. (MDCO +7.1%) to $34 from $30 on the back of the drug developer's previously announced positive results for the Phase III trial of oritavancin. The firm now sees it as a takeout candidate and reiterates an Outperform. Separately, JPMorgan also ups the shares to Overweight. Comment! [On the Move, Healthcare]
Thursday, December 20, 2012, 8:44 AM Medicines Co's (MDCO) oritavancin drug for treating bacterial skin infections met the main goal of a Phase III trial by preventing the spread of the infection and without causing a fever. The study shows that one dose of oritavancin can cure infections, including MRSA, which is a particular problem in hospitals; oritavancin is also as effective as multiple days of infusions of the antibiotic vancomycin. (PR) Comment! [Healthcare]
Wednesday, December 12, 2012, 12:47 PM As a condition of Medicines Company's (MDCO +1.9%) acquisition of Incline Therapeutics, Cadence Pharmaceuticals (CADX +4.9%) has agreed to terminate its exclusive option to acquire Incline. Upon MDCO's closing of the deal, CADX will receive around $13M in termination fees and roughly $1.5M for its Incline stake as well as a pro-rated share of future milestone payments. Comment! [Healthcare, On the Move, M&A]
Wednesday, December 12, 2012, 12:37 PM Medicines Company (MDCO +1.9%) moves up today after agreeing to acquire privately held Incline Therapeutics for $185M plus potential milestone payments. The acquisition gives MDCO access to the development of a disposable and needleless patient-controlled analgesia system for postoperative pain management in hospitals. Additionally, the company also reached a licensing agreement with Bristol-Myers Squibb (BMY +0.6%) on its Recothrom topical treatment to control bleeding during surgery. Comment! [M&A, On the Move, Healthcare]
Tuesday, November 20, 2012, 2:50 PM Shares of The Medicines Company (MDCO +1.7%) move up after being initiated with an Outperform at Oppenheimer. The firm says that the Street has all but ignored MDCO's strong pipeline, noting that Angiomax, its key asset, is worth around $19 per share as a stand alone product. Additionally, Phase III data from its antiplatelet-agent Cangrelor is due by early 2013 at the latest, and results from two Phase III studies of its antibiotic treatment Oritavancin should come some time in the first half of next year as well. Comment! [Healthcare, On the Move]

ltfinger
Potential Downgrades (5/1/13): $HFC, $HIW, $HSNI, $IP, $JNJ, $LPLA, $LYB, $MDCO, $MSCC, $MTD, $NIHD, $NOW, $OSK, $PCH, $PH, $RDEN, $ROC
May 2, 10:35 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Today's Potential Downgrades (3/18/13): , $ILMN, $IOC, $LNKD, $MDCO, $MGA, $MLNX, $MON, $NOW, $OCN, $OII, $PCLN, $PCYC, $PG, $PII, $PLCE
Mar 19, 7:43 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
ARM 3T Trend STT BUY (3/11/13): $ANV, $BBL, $BEAM, $CAJ, $CNH, $DSW, $EC, $GTLS, $JAZZ, $MDCO, $MHFI, $MRC, $QCOR, $RGLD, $SQM, $URBN
Mar 11, 11:06 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Today's Returning Upgrades (3/11/13): $MDCO
Mar 11, 9:35 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
LiveCharts; End of the Week Video Cover the Market and Trade Setups | $MON $STX $MDCO $TWC and others http://bit.ly/TPshr1
Jan 11, 2:11 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Small Cap Stocks Looking Strong In Earnings And Liquidity http://bit.ly/TmxnGr $MDCO $RNF $SIMO $ZIGO @ZetaKap
10/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Liquid Small-Cap Healthcare Stocks Projected For Strong Growth http://bit.ly/PufuoU $ACOR $AVNR $CADX $MDCO $NXTM $QLTI @ZetaKap
8/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
MDCO - 100% Barchart technical buy signal - 10 new highs and up 16.81% in the last month - Relative strength Index 67.86%
7/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
$FTK, $BYD setting up nicely, $MDCO still running, $IRDM at key resistance. No positions yet in them $$ #KSMT
2/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Potential Trades This Week: Looking For Consolidation $IRDM $DUSA $MDCO $SPY $IWM $DIA $QQQ $TBT $TLT #KSMT http://bit.ly/z24CU1
1/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

MDCO The Medicines Company

MDCO

The Medicines Company